证券代码：300119 证券简称：瑞普生物 公告编号：2025-089 瑞普生物股份有限公司 关于部分募集资金专户完成设立、变更、销户 为了规范募集资金的管理和使用，保护投资者权益，根据《证券法》《上市 公司募集资金监管规则》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等相关法律法规的要求及公司《募集资金管理制度》的 相关规定，公司设立了募集资金专项账户，并与相关银行及保荐机构中国银河证 券股份有限公司分别签订了《募集资金三方监管协议》，募集资金在三方监管下 合规使用。 暨签订三方监管协议的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞普生物股份有限公司（以下简称"公司""瑞普生物"）于 2025 年 10 月 24 日召开第五届董事会第二十九次（临时）会议及第五届监事会第二十五次 （临时）会议，审议通过了《关于设立及变更募集资金专户并授权签署三方监管 协议的议案》，同意根据 2021 年向特定对象发行股票部分募集资金投资项目变 更需求，在渤海银行开立新的募集资金专项账户，并变更原在平安银行（账号： 1553500 ...

Group 1 - The China Livestock Breeding Index (930707) shows mixed performance among its constituent stocks, with Zhongmu Co., Ltd. leading the gains at 4.31% [1] - The average price of pork in China's wholesale markets increased by 1.3% to 17.96 yuan per kilogram as of October 27 [1] - Galaxy Securities indicates that losses in October may accelerate the reduction of pig farming capacity, highlighting opportunities in the pig farming industry based on the value of breeding sows and farming efficiency [1] Group 2 - As of September 30, 2025, the top ten weighted stocks in the China Livestock Breeding Index account for 66.06% of the index, including Muyuan Foods, Wens Foodstuff Group, and others [2]

Core Viewpoint - Reap Bio reported significant growth in net profit attributable to shareholders for the first three quarters, driven by revenue expansion, product structure optimization, and cost reduction strategies [1] Financial Performance - The company achieved a substantial increase in net profit attributable to shareholders, primarily due to revenue growth and improved product gross margins [1] - Non-recurring gains for the first three quarters amounted to 93.03 million yuan, an increase of 59.82 million yuan year-on-year, attributed to gains from non-current financial assets and partial equity transfers of subsidiaries [1] Cost Management - The company successfully implemented lean cost reduction and value innovation strategies, enhancing production efficiency and lowering operational costs [1] - Sales and management expense ratios decreased by 0.27 percentage points year-on-year, indicating improved cost management [1]

Core Insights - The company, Ruipu Biotech, announced a change in the use of part of the funds raised from a specific stock issuance, redirecting them towards the construction of a "Biomanufacturing Industrialization Project" with a total investment of 679 million yuan, of which 296 million yuan will come from the raised funds [2] Group 1 - The project aims to establish a demonstration project for the industrialization of tens of thousands of tons of microbial protein, focusing on producing mycelium protein raw materials and related products [2] - The target markets include high-growth sectors such as meat alternatives, protein beverages, protein powders, high-protein health snacks, and dairy products, highlighting the advantages of microbial protein over traditional meat proteins, including lower fishy taste, better texture, lower production costs, and higher amino acid content [2] - The company has already built a pilot production line for mycelium protein and completed the research on the production process, indicating a solid foundation for industrialization and promotion [2] Group 2 - The new production facility is currently under construction, and according to the feasibility study report, the project is expected to generate an annual revenue of 1.3 billion yuan upon full production [2] - The revenue forecast is based on the feasibility study report and may be influenced by market conditions, construction progress, capacity ramp-up, and product promotion, suggesting potential variability in actual performance [2]

Core Viewpoint - The company has significantly improved its raw material drug segment's operating conditions, with a gross margin increase of over 10 percentage points year-on-year, leading to a notable reduction in losses [1] Group 1: Financial Performance - The raw material drug segment's operating conditions have improved significantly this year due to optimized product structure and internal management [1] - The gross margin for the raw material drug segment has increased by more than 10 percentage points compared to the previous year [1] - The company has achieved a significant reduction in losses within this segment [1] Group 2: Future Outlook and Strategies - The company maintains a cautiously optimistic outlook on the future trends of the raw material drug market [1] - Plans to continue enhancing the quality and reducing costs in the raw material drug segment include: - Deepening lean cost reduction through precise diagnosis and optimization of production processes and strengthening centralized procurement management to effectively lower unit production costs [1] - Accelerating overseas market expansion to continue increasing export share [1] - Optimizing product structure to increase the proportion of high-margin products and further enrich the high value-added product matrix to improve overall profitability [1]

Core Viewpoint - The company expresses confidence in its future market positioning for pet-related products, leveraging its terminal advantages through the Zhongrui and Ruipai channels while focusing on mid-to-high-end market strategies [1] Group 1: Market Strategy - The company plans to increase brand promotion and marketing expenses to enhance its market presence [1] - Online channels are currently in a high-investment phase, with the acquisition of Hangzhou Zebra Bingbing's online promotion team and collaborations with top influencers to boost online sales [1] - Future offline efforts will focus on promoting biological products and auxiliary pharmaceuticals, while online efforts will emphasize pet deworming and health products [1] Group 2: Product Development - The company has launched new products this year, including "Chao Bi Xin" and "Miao Pu Jing" deworming medications, as well as the health product "En Qiu Er" [1] - Ongoing development includes new vaccines such as the cat trivalent live vaccine, cat quadrivalent mRNA vaccine, cat infectious peritonitis mRNA vaccine, and dog quadrivalent vaccine to continuously invigorate the pet segment [1]

Core Viewpoint - Guohai Securities report indicates that Ruipu Biotech's net profit attributable to shareholders reached 362 million yuan in the first three quarters of 2025, representing a year-on-year increase of 45.64% [1] Financial Performance - In Q3 2025, the company achieved a net profit of 106 million yuan, up 23.02% year-on-year [1] - The revenue growth rate in Q3 2025 slowed compared to Q2 2025, but the overall performance for the first three quarters still showed rapid growth [1] - Non-operating income confirmed in the first three quarters was 93 million yuan, an increase of 60 million yuan year-on-year [1] Business Development - The company is deepening cooperation to expand into the ruminant vaccine market [1] - It is also laying out plans in the synthetic biology sector to create long-term growth points [1] - The sustained improvement in operational performance is attributed to the company's proactive expansion into new business areas [1]

Core Insights - The company reported a revenue of 2.544 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 13.50%, and a net profit attributable to shareholders of 362 million yuan, up 45.64% year-on-year [1] - In Q3 2025, the company achieved a revenue of 837 million yuan, with a year-on-year increase of 1.44%, and a net profit of 106 million yuan, reflecting a growth of 23.02% year-on-year [1] - The company has made significant advancements in mRNA vaccine development, including obtaining the world's first clinical trial approval for a food animal mRNA vaccine, showcasing its technological strength and forward-looking capabilities in the veterinary vaccine sector [1] Product Development - In Q3, the company received approvals for seven new products across various categories, including biological products, chemical drugs, and antibodies, enhancing its product matrix in the pet and animal medicine sectors [2] - The new products include vaccines for Newcastle disease, infectious bronchitis, avian adenovirus, and several others, which will drive high-quality development for the company [2] - The company has also adjusted the use of some raised funds to support the construction of a biological manufacturing industrialization project, aiming to expand into the new high-quality alternative protein sector [2] Operational Efficiency - The company has improved its profitability model through cost reduction and value innovation, leading to enhanced production efficiency and reduced operational costs [3] - During the reporting period, the sales and management expense ratios decreased by 0.27 percentage points year-on-year [3] - Looking ahead, the company is expected to maintain a competitive edge in the animal health sector and explore new growth opportunities through continued investment in mRNA vaccines and the development of ruminant vaccines [3]

Core Insights - The company has established a pilot production line for mycelium protein and completed the research on the pilot production process, indicating a foundation for industrialization and promotion [1] - A new production facility is currently under construction, which is expected to enhance production capacity [1] - According to the feasibility study report, once the project is fully operational, it is projected to generate an annual revenue of 1.3 billion yuan [1]

Group 1: Financial Events and Policies - The 2025 Financial Street Forum Annual Meeting is taking place from October 27 to 30 in Beijing, with key speeches from the Governor of the People's Bank of China, the head of the Financial Regulatory Administration, and the Chairman of the China Securities Regulatory Commission [2][3] - The People's Bank of China will conduct a 900 billion yuan Medium-term Lending Facility (MLF) operation on October 27, with a one-year term [3][5] - The State Council's report on financial work emphasizes the need for a moderately loose monetary policy to support the real economy and create a favorable financial environment [3] Group 2: Company Earnings Reports - WuXi AppTec reported a net profit of 12.076 billion yuan for the first three quarters, a year-on-year increase of 84.84% [4] - Cambridge Technology's net profit for the first three quarters increased by 70.88% year-on-year [5] - Weicai Technology achieved a net profit of 202 million yuan for the first three quarters, marking a 226.41% year-on-year growth [5] - Guosheng Financial Holdings reported a net profit of 242 million yuan for the first three quarters, up 191.21% year-on-year [6] - Shen Shen Fang A's net profit surged by 2791.57% year-on-year for the first three quarters, reaching 14.5 million yuan [6] - Several companies, including Morning Light Biotechnology and Wen Tai Technology, reported significant year-on-year profit increases of 385.3% and 265.09%, respectively [6][12] Group 3: Company Losses and Declines - Jing Sheng Machinery reported a net profit decline of 69.56% for the first three quarters [9] - China Shenhua's net profit decreased by 10% year-on-year, amounting to 39.052 billion yuan [8] - Health Yuan and Ping An Bank experienced net profit declines of 1.83% and 3.5%, respectively, for the first three quarters [8]